Clinical Trial Update: Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

View source ↗

Summary

This post-authorization observational study reports on cognition and fatigue in relapsing-remitting multiple sclerosis patients treated with Rebif (interferon b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Multiple Sclerosis, Relapsing-Remitting | Status: COMPLETED